Vascular Malformations clinical trials
The registry lists 79 studies for Vascular Malformations across more than 10 countries. 33 are recruiting or about to start. 41 of them are mainly about Vascular Malformations (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10. Counting its 4 narrower conditions too, such as Arteriovenous Fistula: 525 studies, 126 open.
Get an email when these change. Save the Vascular Malformations studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Shanghai Jiao Tong University School of Medicine (4) · Children's Hospital of Philadelphia (3) · Boston Children's Hospital (3) · Mayo Clinic (2) · University Hospital Erlangen (2) · Stanford University (2) · Centre hospitalier de l'Université de Montréal (CHUM) (2) · Radboud University Medical Center (2)
What is being tested here
Drugs under test in Vascular Malformations studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Everolimus | 2 | 0 | 2 |
| Alpelisib | 2 | 0 | 2 |
| Sirolimus | 1 | 2 | 5 |
| Trametinib | 1 | 0 | 2 |
| Bleomycin | 1 | 0 | 2 |
| Topical Sirolimus | 1 | 0 | 2 |
| Mirdametinib | 1 | 0 | 1 |
| Enalapril | 1 | 0 | 1 |
| Thalidomide | 0 | 0 | 3 |
| Timolol | 0 | 0 | 2 |
Drug classes tested here mTOR inhibitors 3 open
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 7
- Nov 2026Treatment of Low-flow Venous Malformations With Electrosclerotherapy. Prospective Observational Study · Istituto Ortopedico Rizzoli
- Dec 2026A 10-Minute Cardiovascular Magnetic Resonance Protocol for Cardiac Disease · McGill University Health Centre/Research Institute of the McGill University Health Centre
- Jan 2027A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations · Murdoch Childrens Research Institute
- Feb 2027Pregnancy in Women With Rare Multisystemic Vascular Diseases: COGRare5 Study · Hospices Civils de Lyon
- Jul 2027Trametinib Treatment for Complicated Vascular Anomalies · West China Hospital
- Sep 2027Bleomycin Electrosclerotherapy (BEST) for Slow-flow Vascular Malformations · Rigshospitalet, Denmark
- Oct 2027A Study of Clinical Practice and Real-world Care of Patients Treated With mTOR, PI3K, and MEK Inhibitors for Extracranial Vascular Anomalies · Novartis Pharmaceuticals
Who these studies take
Of the 22 Vascular Malformations studies recruiting now, 13 (59%) set no upper age limit and 7 (32%) stop at 75 or younger. 15 (68%) take children under 18. 1 (5%) are for women only and 0 (0%) for men only; 3 (14%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 14 (64%) | 14 (64%) |
| 18 | 21 (95%) | 20 (91%) |
| 30 | 21 (95%) | 20 (91%) |
| 40 | 19 (86%) | 18 (82%) |
| 50 | 18 (82%) | 18 (82%) |
| 65 | 18 (82%) | 18 (82%) |
| 75 | 15 (68%) | 15 (68%) |
| 85 | 15 (68%) | 15 (68%) |
Across all 79 studies, recruiting or not: 27% stop at 75 or younger and 20% at 65; 63% take children; 5% are for women only and 0% for men only; 10% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
What changed recently
From the registry's own updates since Oct 13, 2026.
Started recruiting2
- 24VA022; VATCH Alpelisib for TIE2/PIK3CA Pathway VAsOct 19, 2026NCT07543822
- 24VA021; VATCH Trametinib for Ras/MAPK Pathway VAsOct 19, 2026NCT07549646
Newly registered1
- Fetal Embolization for Severe Vein of Galen Malformation - A Feasibility and Safety TrialNov 10, 2026NCT07927725
Studies
Recruiting first, then most recently updated. Showing 50 of 79. Browse all 79 → or search them.
- Fetal Embolization for Severe Vein of Galen Malformation - A Feasibility and Safety TrialNot yet recruitingNCT07927725Not applicable1 country
- Topical TOR-582 Treatment of Epistaxis in HHTNot yet recruitingNCT07667413Phase 11 country
- Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)RecruitingNCT07601425Phase 1/22 countries
- A 10-Minute Cardiovascular Magnetic Resonance Protocol for Cardiac DiseaseRecruitingNCT044646551 country
- 24VA022; VATCH Alpelisib for TIE2/PIK3CA Pathway VAsRecruitingNCT07543822Phase 21 country
- 24VA021; VATCH Trametinib for Ras/MAPK Pathway VAsRecruitingNCT07549646Phase 21 country
- Treatment of Low-flow Vascular Malformations With Bleomycin Electrosclerotherapy (BEST)RecruitingNCT07579962Phase 21 country
- Pregnancy in Women With Rare Multisystemic Vascular Diseases: COGRare5 StudyRecruitingNCT041946191 country
- Lymphatic Anomalies Registry for the Assessment of Outcome DataRecruitingNCT023995271 country
- A Study of Clinical Practice and Real-world Care of Patients Treated With mTOR, PI3K, and MEK Inhibitors for Extracranial Vascular AnomaliesNot yet recruitingNCT07767877
- A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)RecruitingNCT06789913Phase 29 countries
- Patient Reported Outcomes for Vascular Malformations EmbolizatioN (PROVEN)RecruitingNCT041044641 country
- Bleomycin Electrosclerotherapy (BEST) for Slow-flow Vascular MalformationsEnrolling by invitationNCT077205701 country
- Comprehensive HHT Outcomes Registry of the United States (CHORUS)RecruitingNCT062592921 country
- Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Patients With PIK3CA-related Overgrowth Spectrum (PROS) and PIK3CA-related Vascular Malformations (PRVM)RecruitingNCT06975618Phase 1/22 countries
- Treatment of Low-flow Venous Malformations With Electrosclerotherapy. Prospective Observational StudyRecruitingNCT061890921 country
- A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular MalformationsRecruitingNCT05983159Phase 21 country
- A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular AnomaliesNot yet recruitingNCT07477548Phase 2
- Imaging Lymphatic Function in Normal Subjects and in Persons With Lymphatic DisordersEnrolling by invitationNCT008335991 country
- Microwave Ablation for Treatment of Vascular Malformations: Efficacy and SafetyNot yet recruitingNCT07404670Not applicable
- Institutional Registry of Rare DiseasesRecruitingNCT065737231 country
- An Open-Label, Single-Arm Exploratory Clinical Study of Everolimus for the Treatment of Vascular MalformationsRecruitingNCT07037238Phase 21 country
- Diagnostic Imaging of Vascular Malformations Using MSOT and ULMNot yet recruitingNCT069942601 country
- International Registry of Congenital Portosystemic Shunt (IRCPSS)Enrolling by invitationNCT0604190616 countries
- A Study of Enalapril in Treatment of Venous MalformationsRecruitingNCT06788314Phase 21 country
- Radiofrequency Ablation of Vascular AnomaliesNot yet recruitingNCT06803667Not applicable
- Identification of Biomarkers for Patients with Vascular AnomaliesRecruitingNCT030011801 country
- Treatment of Brain AVMs (TOBAS) StudyRecruitingNCT02098252Not applicable6 countries
- Investigation of Lipedema, Lymphedema and Vascular Malformations by Multispectral Optoacoustic Tomography (MSOT)Enrolling by invitationNCT063993671 country
- Role of Sirolimus in Treatment of Microcystic , Mixed Lymphatic and Vascular MalformationsRecruitingNCT061607391 country
- International Lymphatic Disease and Lymphedema RegistryRecruitingNCT013367901 country
- Aneurysm Genetic Risk in Patients With QIB ChangesRecruitingNCT053171691 country
- Efficacy and Safety of Sirolimus in Vascular Anomalies That Are Refractory to Standard CareRecruitingNCT02638389Phase 33 countries
- MiDura-Study (Neuro-Patch in Duraplasty)CompletedNCT041891722 countries
- AVAST Anomalies Vasculaires Associées au Syndrome de Turner (Vascular Abnormalities Associated With Turner Syndrome)TerminatedNCT022504561 country
- Intralesional Bleomycin Sclerotherapy for Low-Flow Vascular Malformations of the Head and NeckCompletedNCT07728825Phase 41 country
- Beacon Tip Sizing Catheter and Slip-Cath Beacon Tip Catheter StudyCompletedNCT069869541 country
- SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic MalformationsActive, not recruitingNCT06239480Phase 31 country
- National Evaluation of Patients With PIK3CA-Related Overgrowth Spectrum (PROS)CompletedNCT055638311 country
- Topical Sirolimus in Cutaneous Lymphatic MalformationsCompletedNCT03972592Phase 21 country
- Comparative Study Between Sclerosing Agents Used in Treatment of Vascular MalformationCompletedNCT07320430Not applicable1 country
- Topical Rapamycin/Sirolimus for Complicated Vascular Anomalies and Other Susceptible LesionsTerminatedNCT04172922Phase 11 country
- suPERficial Slow-flow Vascular malFORMations Treated With sirolimUSCompletedNCT02509468Phase 21 country
- Transvenous Approach for the Treatment of Cerebral Arteriovenous MalformationsCompletedNCT03691870Not applicable2 countries
- Trametinib Treatment for Complicated Vascular AnomaliesActive, not recruitingNCT07072403Phase 1/21 country
- SelfWrap-Assisted Arteriovenous FistulasActive, not recruitingNCT05418816Not applicable1 country
- Safety and Efficacy Of Amber Peripheral Liquid Embolic SystemActive, not recruitingNCT06456125Not applicable1 country
- Characterization of the Pathogenesis of Primary and Secondary Lymphatic DisordersTerminatedNCT021561151 country
- A Study to Compare Vincristine to Sirolimus for Treatment of High Risk Vascular TumorsTerminatedNCT02110069Phase 21 country
- Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of ConceptCompletedNCT01752049Phase 1/21 country